Pressebereich

Actions

130522 PR VI Orsiro BIOFLOW II EN

Actions

BIOTRONIK Orsiro Hybrid Drug-Eluting Stent lives up to Abbott’s XIENCE PRIM standards

Positive 9 month results from BIOFLOW-II clinical trial and 12 month results from BIOFLOW-III registry presented at EuroPCR congress






Please contact us if you require further information.

${loading}